GlassScriptPhysician profile
Marcus G Williams
NPI 1730177155
$2,015.85
in general payments reported to CMS, 2019-2025
25 companies · $48.47 in 2025
The $48.47 reported for 2025 was less than what a typical Thoracic Surgery (Cardiothoracic Vascular Surgery) provider received nationally (typical 2025 total: $796).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $610 · 2020: $67.50 · 2021: $452 · 2022: $394 · 2023: $396 · 2024: $47.59 · 2025: $48.47.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $493.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $492.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $364.77 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $348.81 | 2019-2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $233.99 | 2019-2025 | Lifevest |
| Abiomed | $217.97 | 2019-2021 | |
| Atricure, INC. | $169.62 | 2022 | |
| Amgen INC. | $120.74 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $73.41 | 2019-2021 | |
| Angiodynamics, INC. | $59.10 | 2022 | |
| Irhythm Technologies, INC. | $59.09 | 2019-2023 | Zio Xt Patch |
| Daiichi Sankyo INC. | $53.01 | 2023-2024 | Injectafer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.38 | 2019-2023 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $35.04 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $34.96 | 2019-2021 | |
| Philips North America LLC | $31.93 | 2019 | |
| Pfizer INC. | $23.09 | 2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $21.87 | 2019 | |
| Baxter Healthcare | $18.03 | 2022 | |
| Kiniksa Pharmaceuticals, LTD. | $16.97 | 2023 | Arcalyst |
| Actelion Pharmaceuticals US, INC. | $16.74 | 2023 | Uptravi, Opsumit |
| Abbott Laboratories | $15.59 | 2022 | |
| Livanova USA, INC. | $14.48 | 2023 | Lifesparc |
| Kowa Pharmaceuticals America, INC. | $14.33 | 2019 | |
| Astellas Pharma US INC | $12.42 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $11.34 | 2019 | |
| Gilead Sciences, INC. | $11.17 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marcus Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.